Novozymes A/S (NVZMY) Income Statement Analysis

See more : Beijing Chieftain Control Engineering Technology Co., Ltd. (300430.SZ) Income Statement Analysis – Financial Results

Complete financial analysis of Novozymes A/S (NVZMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novozymes A/S, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.

You may be interested

JITF Infralogistics Limited (JITFINFRA.BO) Income Statement Analysis – Financial Results
Reevo S.P.A. (REEVO.MI) Income Statement Analysis – Financial Results
Algorhythm Holdings Inc. (RIME) Income Statement Analysis – Financial Results
Bancorp. of Southern Indiana (BCSO) Income Statement Analysis – Financial Results
Sydinvest Virksomhedsobligationer HY KL (SYIVOHYADKK.CO) Income Statement Analysis – Financial Results

Novozymes A/S (NVZMY)

Industry: Chemicals - Specialty

Sector: Basic Materials

Website: https://www.novozymes.com

About Novozymes A/S

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	17.90B	17.55B	14.95B	14.01B	14.37B	14.39B	14.53B	14.14B	14.00B	12.46B	11.75B	11.23B	10.51B	9.72B	8.45B	8.15B	7.44B	6.80B	6.28B	6.02B	5.80B	5.64B
Cost of Revenue	8.18B	7.98B	6.33B	6.16B	6.42B	6.14B	6.12B	6.02B	5.87B	5.31B	5.03B	4.81B	4.60B	4.31B	3.75B	3.79B	3.49B	3.15B	2.94B	2.85B	2.80B	2.73B
Gross Profit	9.72B	9.58B	8.62B	7.85B	7.95B	8.26B	8.41B	8.13B	8.13B	7.15B	6.72B	6.42B	5.91B	5.41B	4.70B	4.36B	3.95B	3.66B	3.35B	3.18B	3.00B	2.91B
Gross Profit Ratio	54.32%	54.56%	57.68%	56.04%	55.34%	57.37%	57.90%	57.46%	58.06%	57.38%	57.18%	57.17%	56.21%	55.66%	55.63%	53.51%	53.09%	53.73%	53.26%	52.77%	51.77%	51.54%
Research & Development	2.02B	2.00B	2.01B	1.94B	1.97B	1.87B	1.91B	1.87B	1.90B	1.84B	1.53B	1.53B	1.46B	1.36B	1.21B	1.10B	995.00M	880.00M	793.00M	775.00M	749.00M	713.00M
General & Administrative	959.00M	952.00M	859.00M	739.00M	838.00M	792.00M	831.00M	810.00M	876.00M	857.00M	824.00M	808.00M	778.00M	762.00M	751.00M	745.00M	675.00M	650.00M	632.00M	595.00M	587.00M	575.00M
Selling & Marketing	2.37B	2.27B	1.94B	1.58B	1.63B	1.57B	1.62B	1.62B	1.57B	1.41B	1.48B	1.42B	1.38B	1.24B	1.12B	1.06B	921.00M	844.00M	748.00M	750.00M	730.00M	729.00M
SG&A	3.32B	3.22B	2.80B	2.32B	2.47B	2.36B	2.45B	2.43B	2.45B	2.26B	2.30B	2.23B	2.15B	2.00B	1.87B	1.81B	1.60B	1.49B	1.38B	1.35B	1.32B	1.30B
Other Expenses	405.00M	-75.00M	-66.00M	-14.00M	-26.00M	-43.00M	-63.00M	-117.00M	-98.00M	-102.00M	-13.00M	9.00M	-50.00M	-69.00M	-64.00M	-47.00M	-123.00M	-59.00M	-34.00M	-31.00M	-44.00M	-56.00M
Operating Expenses	5.75B	5.15B	4.74B	4.24B	4.41B	4.19B	4.30B	4.18B	4.25B	4.00B	3.82B	3.68B	3.57B	3.30B	3.01B	2.86B	2.47B	2.32B	2.14B	2.09B	2.02B	1.96B
Cost & Expenses	13.92B	13.13B	11.07B	10.40B	10.83B	10.32B	10.42B	10.20B	10.12B	9.31B	8.85B	8.49B	8.17B	7.61B	6.76B	6.64B	5.96B	5.46B	5.08B	4.93B	4.82B	4.70B
Interest Income	24.00M	18.00M	18.00M	10.00M	90.00M	10.00M	7.00M	5.00M	4.00M	9.00M	5.00M	13.00M	208.00M	113.00M	153.00M	263.00M	130.00M	134.00M	76.00M	89.00M	223.00M	131.00M
Interest Expense	173.00M	102.00M	102.00M	63.00M	86.00M	13.00M	27.00M	31.00M	31.00M	58.00M	66.00M	74.00M	133.00M	107.00M	220.00M	348.00M	226.00M	256.00M	132.00M	98.00M	190.00M	178.00M
Depreciation & Amortization	1.39B	1.46B	1.37B	1.23B	1.17B	1.01B	1.04B	974.00M	953.00M	866.00M	738.00M	703.00M	208.00M	113.00M	564.00M	556.00M	490.00M	469.00M	462.00M	519.00M	523.00M	532.00M
EBITDA	5.47B	6.12B	5.20B	4.85B	5.07B	5.04B	5.19B	4.89B	4.77B	4.20B	3.56B	3.36B	2.55B	2.23B	2.41B	2.32B	2.10B	1.94B	1.74B	1.67B	1.73B	1.61B
EBITDA Ratio	30.57%	34.60%	34.76%	34.26%	32.84%	34.60%	35.74%	34.36%	34.08%	31.73%	29.86%	29.92%	24.24%	22.93%	28.47%	28.52%	28.25%	10.92%	27.77%	28.19%	29.78%	28.54%
Operating Income	3.98B	4.63B	4.01B	3.65B	4.04B	4.07B	4.05B	3.95B	3.88B	3.38B	2.90B	2.75B	2.34B	2.12B	1.69B	1.50B	1.48B	1.34B	1.21B	1.09B	982.00M	947.00M
Operating Income Ratio	22.21%	26.37%	26.80%	26.06%	28.10%	28.28%	27.85%	27.90%	27.74%	27.16%	24.70%	24.43%	22.26%	21.77%	19.98%	18.46%	19.91%	19.70%	19.20%	18.09%	16.92%	16.78%
Total Other Income/Expenses	-67.00M	-73.00M	-83.00M	-131.00M	-240.00M	-134.00M	-171.00M	-65.00M	-263.00M	-105.00M	-142.00M	-161.00M	75.00M	6.00M	-67.00M	-85.00M	-96.00M	-122.00M	-56.00M	-33.00M	33.00M	-47.00M
Income Before Tax	3.91B	4.56B	3.92B	3.52B	3.80B	3.94B	3.88B	3.88B	3.62B	3.28B	2.76B	2.58B	2.42B	2.12B	1.62B	1.42B	1.39B	18.00M	1.15B	1.08B	1.02B	900.00M
Income Before Tax Ratio	21.84%	25.96%	26.25%	25.13%	26.43%	27.35%	26.67%	27.44%	25.86%	26.32%	23.49%	23.00%	22.98%	21.83%	19.19%	17.42%	18.62%	0.26%	18.31%	17.94%	17.49%	15.95%
Income Tax Expense	870.00M	870.00M	779.00M	695.00M	644.00M	709.00M	756.00M	831.00M	796.00M	754.00M	558.00M	568.00M	587.00M	509.00M	427.00M	357.00M	343.00M	-307.00M	289.00M	288.00M	280.00M	253.00M
Net Income	3.02B	3.68B	3.15B	2.83B	3.15B	3.23B	3.12B	3.05B	2.82B	2.53B	2.20B	2.02B	1.83B	1.61B	1.19B	1.06B	1.04B	911.00M	861.00M	793.00M	735.00M	647.00M
Net Income Ratio	16.89%	20.94%	21.04%	20.16%	21.94%	22.42%	21.46%	21.57%	20.16%	20.27%	18.73%	17.94%	17.39%	16.60%	14.13%	13.04%	14.01%	13.39%	13.71%	13.16%	12.67%	11.47%
EPS	10.88	13.29	11.32	10.07	11.06	11.11	10.56	10.15	9.23	8.10	7.01	6.42	5.80	5.15	3.85	3.43	3.37	2.90	2.63	2.32	2.09	1.79
EPS Diluted	10.88	13.19	11.23	10.02	11.01	11.03	10.49	10.06	9.12	8.02	6.93	6.33	5.71	5.05	3.79	3.37	3.28	2.82	2.57	2.27	2.07	1.78
Weighted Avg Shares Out	277.94M	276.64M	277.92M	280.43M	285.11M	290.42M	295.34M	300.47M	306.00M	311.90M	313.76M	313.98M	315.16M	313.18M	310.27M	309.35M	309.57M	314.37M	327.31M	341.38M	352.30M	361.68M
Weighted Avg Shares Out (Dil)	277.87M	278.73M	280.23M	282.02M	286.55M	292.36M	297.20M	303.12M	309.37M	315.08M	317.41M	318.28M	319.96M	319.38M	315.36M	315.01M	318.12M	322.52M	335.34M	349.25M	354.33M	362.80M

Novozymes A/S (NVZMF) Q3 2022 Earnings Call Transcript

November 4, 2022seekingalpha.com

Novozymes A/S (OTCPK:NVZMF) Q3 2022 Earnings Conference Call November 3, 2022 4:00 AM ET Company Participants Tobias Cornelius Bjorklund - Head-Investor Relations Ester Baiget - Chief Executive Officer Lars Green - Chief Financial Officer Tina Fanoe - Executive Vice President-Agriculture...

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

Novozymes A/S (NVZMY) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories